This may also explain the lower efficiency and efficacy of IFN-dependent LCMV therapy on B16F10 (Fig. 2f) compared with MOPC (Fig. 2a) or MC38 colon cancer (Fig. 2e). This evidence concerns the gene IFNA1 and colonic neoplasm.